Hemab Therapeutics Holdings, Inc.(COAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

COAG Hemab Therapeutics Holdings, Inc.

Market Closed 07-02 16:00:00 EDT

31.00

-1.50

-4.62%

盘后31.20

+0.20+0.65%

18:25 EDT

High33.21	Low30.32	Vol245.39K
Open32.51	D1 Closing32.50	Amplitude8.89%
Mkt Cap1.45B	Tradable Cap519.25M	Total Shares46.71M
T/O7.63M	T/O Rate1.47%	Tradable Shares16.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":31,"timestamp":1783022400000,"preClose":32.5,"halted":0,"volume":245390,"hourTrading":{"tag":"盘后","latestPrice":31.2,"preClose":31,"latestTime":"18:25 EDT","volume":11330,"amount":353536.06,"timestamp":1783031114714,"change":0.2,"changeRate":0.006452,"amplitude":0.021935},"delay":0,"changeRate":-0.046153846153846156,"floatShares":16750000,"shares":46705400,"eps":-1.526,"marketStatus":"Market Closed","change":-1.5,"latestTime":"07-02 16:00:00 EDT","open":32.51,"high":33.21,"low":30.32,"amount":7632505.0423,"amplitude":0.088923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.526,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":32.5,"preHourTrading":{"tag":"盘前","latestPrice":31.95,"preClose":32.5,"latestTime":"09:23 EDT","volume":927,"amount":30704.43699,"timestamp":1782998583083,"change":-0.55,"changeRate":-0.016923,"amplitude":0.036923},"postHourTrading":{"tag":"盘后","latestPrice":31.2,"preClose":31,"latestTime":"18:25 EDT","volume":11330,"amount":353536.06,"timestamp":1783031114714,"change":0.2,"changeRate":0.006452,"amplitude":0.021935},"volumeRatio":0.9201788576894295},"requestUrl":"/m/hq/s/COAG/wiki","defaultTab":"wiki","newsList":[{"id":"2646350582","title":"Hemab Therapeutics Plans First-in-human Study of Hmb-003 Plasmin Inhibitor in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646350582","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646350582?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:00","pubTimestamp":1782478858,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics plans first-in-human study of HMB-003 plasmin inhibitor in 2H 2026Hemab Therapeutics flagged new first-in-human results for HMB-002 in Von Willebrand disease, scheduled for presenta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLlZVT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","COAG","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644776864","title":"Major Investor Quietly Ramps Up Stake in Hemab Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2644776864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644776864?lang=en_us&edition=fundamental","pubTime":"2026-06-18 10:06","pubTimestamp":1781748394,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on June 17, 2026. Ra Capital Management, LLC, a significant s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COAG","BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644872202","title":"RA Capital Management reports Hemab Therapeutics common stock purchase worth $1.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644872202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644872202?lang=en_us&edition=fundamental","pubTime":"2026-06-18 06:25","pubTimestamp":1781735103,"startTime":"0","endTime":"0","summary":"RA Capital Management, a 10% owner of Hemab Therapeutics Holdings, reported open-market purchases of 67,669 common shares at about $24.89-$24.98.RA Capital Healthcare Fund’s stake rose to 6,444,637 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL11ZqyF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management reports Hemab Therapeutics common stock purchase worth $1.69 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644710949","title":"Hemab Therapeutics Hldgs Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2644710949","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644710949?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:24","pubTimestamp":1781691840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 06:24 ET (10:24 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644871098","title":"Hemab Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2644871098","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644871098?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:06","pubTimestamp":1781690804,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $40 price target Hemab is a mid-stage biotech building “first...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","COAG","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644172517","title":"Hemab Therapeutics Holdings, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2644172517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644172517?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:02","pubTimestamp":1781690563,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nAZN4T2ST5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644715008","title":"U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower","url":"https://stock-news.laohu8.com/highlight/detail?id=2644715008","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644715008?lang=en_us&edition=fundamental","pubTime":"2026-06-17 15:16","pubTimestamp":1781680605,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, WelltowerJune 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4N42P0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAT","DOGD","VTR","KLAC","R","CTRE","KLAG","SNDR","GRDN","ARWR","INVH","LU2298064838.USD","LU0011850046.USD","AMH","LRCU","DDOG","IONS","LU2065731478.USD","FIGG","CMI","LSTR","SBRA","CTSH","LRCX","CF","AMAT","VMI","LU2360032135.SGD","HR","GH","JAN","FIG","XRN","LU0158827781.USD","MATX","OHI","LDOS","HUMA","AIZ","CRI","DOC","GKOS","WELL","COAG","FDX","HUN","CNK","KMB","JBHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640319729","title":"Novo Holdings portfolio company Hemab Therapeutics raises $346.7 million in Nasdaq IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640319729","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640319729?lang=en_us&edition=fundamental","pubTime":"2026-06-01 15:53","pubTimestamp":1780300423,"startTime":"0","endTime":"0","summary":"Novo Holdings portfolio company Hemab Therapeutics completed a Nasdaq IPO on May 1, 2026, raising $346.7 million.Nearly 17 million shares sold in an oversubscribed offering priced above the marketed range; stock closed up nearly 90% on day one.Proceeds earmarked to advance clinical trials for prophylactic treatments targeting rare bleeding and thrombosis disorders.FDA granted Breakthrough Therapy Designation in March 2026 for lead asset sutacimig to prevent bleeding episodes in Glanzmann thrombasthenia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL9Td55K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638160635","title":"Hemab Therapeutics Hldgs Initiated at Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2638160635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638160635?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:08","pubTimestamp":1779793680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 07:08 ET (11:08 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0096364046.USD","BK4504","LU2471134796.USD","LU0868494617.USD","LU0251142724.SGD","LU0345770993.USD","LU0742534661.SGD","LU1668664300.SGD","LU0251131958.USD","LU1894683348.USD","GSX","LU2237443382.USD","LU2471134952.CNY","LU1894683264.USD","LU0942090050.USD","LU2237443622.USD","BK4516","BK4139","BK4552","LU0048573561.USD","BK4588","LU2750360641.GBP","LU2237443895.HKD","IE00B19Z3B42.SGD","BK4550","LU1868836914.USD","IE0004086264.USD","LU1868836591.USD","IE0034235188.USD","LU1868837300.USD","LU2237443978.SGD","LU1804176565.USD","LU2471134879.HKD","LU0345770308.USD","LU1791807156.HKD","LU0106831901.USD","LU0868494708.USD","LU2750360997.AUD","LU2237443465.HKD","IE0004091025.USD","LENZ","LU2265009873.SGD","BK4533","COAG","LU2237438978.USD","LU0061475181.USD","BK4007","LU2471134523.USD","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638590557","title":"Hemab Therapeutics initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2638590557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638590557?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:15","pubTimestamp":1779786941,"startTime":"0","endTime":"0","summary":"Jefferies analyst Maury Raycroft initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $39 price target The company is positioned t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638985805","title":"Hemab Therapeutics Holdings Inc : Jefferies Initiates Coverage With Buy Rating; Price Target $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2638985805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638985805?lang=en_us&edition=fundamental","pubTime":"2026-05-26 13:07","pubTimestamp":1779772062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN41Z101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637361026","title":"Major Investor Quietly Ups Bet on Hemab Therapeutics in Fresh Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361026","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637361026?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:12","pubTimestamp":1779415969,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on May 21, 2026. Significant shareholder RA Capital Managemen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ups-bet-on-hemab-therapeutics-in-fresh-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ups-bet-on-hemab-therapeutics-in-fresh-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","COAG","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637354974","title":"RA Capital Management buys Hemab Therapeutics shares worth $120,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2637354974","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637354974?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:21","pubTimestamp":1779394860,"startTime":"0","endTime":"0","summary":"RA Capital Management, a 10% owner of Hemab Therapeutics Holdings, reported open-market purchases of 4,798 common shares at weighted average prices of $24.97 and $24.94.The RA Capital Healthcare Fund holding rose to 6,376,968 shares.Separate RA Capital-controlled positions disclosed alongside the filing included 1,009,052 shares held by Nexus Fund II, 354,938 shares held by Nexus Fund IV.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7mtZx2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management buys Hemab Therapeutics shares worth $120,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637427380","title":"Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637427380","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637427380?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:08","pubTimestamp":1779361724,"startTime":"0","endTime":"0","summary":"Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637385380","title":"Hemab Q1 FY26 net loss widens to $22.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637385380","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637385380?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:01","pubTimestamp":1779361295,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics posted a first-quarter net loss of $22.7 million, widening from $15.3 million a year earlier.Research and development costs climbed to $19.5 million from $14.1 million, while general and administrative expense rose to $4.2 million from $2.5 million.Cash, cash equivalents and marketable securities totaled $163.5 million at March 31, down from $185.5 million at the end of 2025; net cash used in operating activities increased to $21.6 million from $13 million.An upsized May IPO raised gross proceeds of $346.7 million at $18 a share, with net proceeds of about $317.2 million; the company sees its cash resources funding operations into 2029.Sutacimig won FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, with a Phase 3 pivotal trial expected to start in the second half of 2026; Phase 2 data for Factor VII deficiency and Phase 1/2 data for HMB-002 in von Willebrand disease are expected in late 2026 or early 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLRS0FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NDAQ","BK4112","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4139","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","COAG","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380100","title":"Hemab Therapeutics Holdings Inc - Q1 Net Loss $22.7 Mln, or $23.98 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380100?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAPLWH0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638701","title":"Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637638701?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361200,"startTime":"0","endTime":"0","summary":"Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq. Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026  -- Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the first quarter ended March 31, 2026 and noted recent business highlights.\"As a public company we continue our journey to accelerate progress and broaden impact for people living with serious coagulation disorders with strong momentum across our clinical programs,\" said Benny Srensen, Chief Executive Officer of Hemab Therapeutics. \"The Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia recognizes both the potential for sutacimig to address a significant unmet need, and the urgency of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","BK4007","BK4539","BK4585","EMA","LENZ","BK4081","GT","BK4139","BK4119","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635972775","title":"Major Investor Quietly Ramps Up Stake in Hemab Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2635972775","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635972775?lang=en_us&edition=fundamental","pubTime":"2026-05-15 10:11","pubTimestamp":1778811112,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on May 14, 2026. Significant shareholder RA Capital Managemen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","LENZ","BK4007","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635172183","title":"RA Capital Management reports Hemab Therapeutics common share purchase worth $159,036.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2635172183","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635172183?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:21","pubTimestamp":1778793711,"startTime":"0","endTime":"0","summary":"RA Capital Management reported a purchase of 6,387 Hemab Therapeutics Holdings common shares at a weighted average price of $24.9.RA Capital Healthcare Fund held 6,372,170 shares following transaction.Nexus Fund II held 1,009,052 shares; Nexus Fund IV held 354,938 shares.Peter Kolchinsky, Manager, signed filing on behalf of reporting group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL2hcdzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management reports Hemab Therapeutics common share purchase worth $159,036.30","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723658","title":"Hemab Therapeutics files initial beneficial ownership statement for AI DEN-MAB LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723658?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:06","pubTimestamp":1778789171,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics filed Form 3 initial beneficial ownership statement covering 4,876,344 shares of Common Stock held directly by AI DEN-MAB LLC.Filing listed AI DEN-MAB LLC as 10% owner, with AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management LLC, and Len Blavatnik also reported as 10% owners through indirect beneficial ownership.Date of event triggering filing was 05/04/2026; filing was signed 05/14/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is sol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL3HFx09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":0.1183},{"period":"1month","weight":0.1285},{"period":"3month","weight":0.7222},{"period":"ytd","weight":0.7222}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hemab Therapeutics Holdings, Inc.(COAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Hemab Therapeutics Holdings, Inc.(COAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Hemab Therapeutics Holdings, Inc.,COAG,Hemab Therapeutics Holdings, Inc.股票,Hemab Therapeutics Holdings, Inc.股票老虎,Hemab Therapeutics Holdings, Inc.股票老虎国际,Hemab Therapeutics Holdings, Inc.行情,Hemab Therapeutics Holdings, Inc.股票行情,Hemab Therapeutics Holdings, Inc.股价,Hemab Therapeutics Holdings, Inc.股市,Hemab Therapeutics Holdings, Inc.股票价格,Hemab Therapeutics Holdings, Inc.股票交易,Hemab Therapeutics Holdings, Inc.股票购买,Hemab Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hemab Therapeutics Holdings, Inc.(COAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Hemab Therapeutics Holdings, Inc.(COAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction